Skip to main content
Premium Trial:

Request an Annual Quote

Telo Genomics, Mayo Clinic Collaborate on Multiple Myeloma Clinical Studies

NEW YORK – Telo Genomics said Friday it will collaborate with Mayo Clinic on clinical studies to evaluate and validate the company's proprietary telomere analytics as a prognostic solution for multiple myeloma. 

The studies were designed to include two retrospective phases, with the potential of a third prospective phase. The first phase of the studies is expected to launch in the first quarter of 2020. 

For each phase, Telo's telomere analytics will be used to predict the progression of multiple myeloma precursors to full stage multiple myeloma and predict patient responses to first-line therapy at the point of diagnosis. The studies will be led by Shaji Kumar at the Mayo Clinic in Rochester, Minnesota. 

"These studies are foundational to advance Telo-MM tests towards commercialization," Telo Genomics CEO Sherif Louis said in a statement. The company performs quantitative analysis of telomeres with a particular focus on liquid biopsy diagnostics and prognostics. It uses TeloView, a software platform, to quantify specific features of a patient's telomeres in 3-D. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more